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The rat liver soluble catechol-0-methyltransferase (EC 2.1.1.6.) has been purified utilizing a combination of conventional chromatography and 
HPLC. The purified enzyme has a molecular mass of 25 kDa, a p1 of 5.1, and exists in two forms which differ in the nature of their intramolecular 
disulfide bonds. This difference causes these two protein forms to behave differently in reversed phase chromatography. 
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1. INTRODUCTION 
Catechol-0-methyltransferase (EC 2.1.1.6; COMT) 
catalyzes the transfer of the methyl group of S- 
adenosyl-L-methionine to the hydroxyl group of 
catechols and catecholamines in the presence of 
magnesium [1,2]. The enzyme has a physiological role 
in the inactivation of catecholamine hormones and 
nemotransmitters as well as in the detoxification of a 
variety of xenobiotic amines and drugs [3]. COMT en- 
zyme activity has been demonstrated in many mam- 
malian tissues with the highest levels in the liver, 
kidney, uterus and placenta [4]. 0-methylation of cir- 
culating catecholamines occurs preferentially in the 
liver, which makes it a potential source for purification 
of the COMT enzyme [5]. Several reports on the 
purification and properties of rat liver S-COMT have 
been published with various results concerning its 
molecular weight, isoelectric point, subunit structure 
and stability [ 1,4- 181. In addition, rat liver COMT has 
been found in both soluble and membrane bound 
forms [2-4,6,9,13], of which the soluble enzyme seems 
to predominate in the rat liver (95-99%) [19]. Ongoing 
investigations of the COMT enzyme gene, including 
cloning and sequencing, will soon give more informa- 
tion about the molecular biology of the enzyme [20]. 
To support these investigations, we have developed a 
method to obtain pure COMT. The pure enzyme per- 
mitted production of specific antibodies for clone 
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detection as well as derivation of peptide sequences to 
be used for oligonucleotide probing. 
2. MATERIALS AND METHODS 
2.1. Purification of rat liver S-COMT 
All purification steps, except RP-chromatography, were perform- 
ed at +4”C. The enzymatic activity was measured as described [21] 
by monitoring at 254 nm. Rat livers (50 g) were homogenized in 
150 ml of sodium phosphate pH 7.2 and 0.2 mM phenylmethyl- 
sulfonylfluoride. The homogenate was first centrifuged at 10000 x g 
for 25 min, then at 30000 x g for 25 min, and finally at 100000 x 
g for 1 h. All the pellets were discarded. The pH of the resulting solu- 
tion was adjusted to 5.1 with acetic acid, and the mixture was kept 
at 0°C for 30 min and then centrifuged (15000 x g, 20 min). The pH 
of the clear supernatant (200 ml) was adjusted to 7.2 with 1 M 
sodium hydroxide and the solution mixed with hydroxyapatite 
(100 ml) (Bio-Gel HT, Bio-Rad). The mixture was stirred for 20 min 
and centrifuged (15000 x g, 20 min). Ammonium sulfate was added 
(65% saturation at 0°C) and the precipitate collected after centrifuga- 
tion (30000 x 8, 20 min). The precipitate was dissolved in 30 ml 
20 mM sodium acetate, pH 4.8 and applied (10 ml) on a Bio-Gel 
P-100 column. The fractions which contained COMT activity were 
pooled and concentrated by ultrafiltration (Filtron Novacell NClO). 
Subsequently, cation-exchange chromatography was performed on 
a Mono-S (HR 515, Pharmacia) column equilibrated with 20 mM 
sodium acetate, pH 4.8 and eluted with a linear gradient of sodium 
chloride (O-O.5 M in 20 min). The fractions with COMT activity 
were pooled and prepared for anion-exchange chromatography by 
ultrafiltration. Anion-exchange chromatography was performed on a 
Mono Q (HR 5/5, Pharmacia) column. The active fraction from the 
Mono-Q column was subjected to RP-chromatography. 
2.2. Alkylation 
Proteins collected manually from RP-columns were dried, 
alkylated 1221 and desalted by RP-chromatography. The eluted pro- 
teins were then dried in a vacuum centrifuge. 
2.3. Digestion with trypsin and separation of tryptic peptides 
The proteins were dissolved in 100~1 0.1 M ammonium bicar- 
bonate and treated with 4% (w/w) TPCK-trypsin (Sigma) for 8 h. 
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Resulting peptides were separated by RP-chromatography and the in- 
dividual peptides collected and dried. 
2.4. Amino acid sequencing 
The peptides or proteins were degraded in a gas/pulsed liquid se- 
quencer [23] after application on polybrene (2 mg) pretreated glass 
fiber filters. In addition, proteins were analyzed after electrophoretic 
transfer from SDS-PAGE onto a polyvinylidene difluoride mem- 
brane [24]. 
2.5. Antibody production 
COMT antibodies were raised by immunizing rabbits in lymph 
nodes [l 11. All blood samples were analyzed for COMT antibodies 
using Western immunoblotting [25] and Protoblot (Promega) 
detection. 
2.6. Chromatofocusing and SDS-PAGE 
Chromatofocusing was performed on a Mono-P (HR 5/20, Phar- 
macia) column equilibrated with 20 mM bis-Tris-HCI, pH 7.2 using 
a pH gradient from 7 to 4 (Polybuffer 74, Pharmacia). Fractions of 
0.5 ml were collected and measured for pH and COMT activity. 
Analytical SDS-PAGE was according to Laemmli [26]. 
3. RESULTS AND DISCUSSION 
The purification procedure presented in this paper is 
a combination of conventional chromatography and 
HPLC. 
The first steps include homogenization of the rat 
liver and centrifugations to clarify the supernatant. The 
supernatant (140 ml) after the first centrifugation con- 
tained 1420 U of COMT activity and 1400 mg of total 
protein corresponding to a spec. act. of 1 .O U/mg pro- 
tein. The clarification steps were followed by precipita- 
tion and adsorption of unwanted components as well as 
ammonium sulfate precipitation of the COMT enzyme. 
It has been reported that the COMT enzyme is labile 
after ammonium sulfate fractionation [9] but in our 
hands this method has given a fairly stable enzyme 
preparation also for longer (several months) storage at 
-20°C. 900 U of COMT activity could be recovered in 
the dissolved ammonium sulfate precipitate (9 ml) cor- 
responding to a 69% yield from the first centrifugate 
(1420 U). The preliminary purification steps were 
followed by gel filtration. COMT activity was found 
only in one symmetrical peak clearly separated from 
most of the other proteins corresponding to an ap- 
parent molecular mass of 25 kDa (Fig. 1A). To op- 
timize the ion-exchange chromatography steps the p1 of 
the enzyme was determined by chromatofocusing, in 
which the enzymatic activity eluted at pH 5.1. The ac- 
tive fraction from the Bio-Gel P-100 column was sub- 
jected to cation exchange chromatography, in which 
the COMT enzymatic activity did not correspond to 
any visible protein peak (not shown). The COMT active 
fraction from the Mono-S column was, after changing 
the buffer, subjected to anion exchange chromato- 
graphy. The main activity then corresponded to one 
protein peak (7.56 min), but some minor COMT activi- 
ty was also found in the later fractions (Fig. 1B). The 
specific activity of the collected main fraction (Fig. 1B) 
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Fig. 1. Chromatograms from different purification steps of COMT. 
(A) Gel filtration on a Bio-Gel P-100 column (2.5 x 90 cm, 20 mM 
sodium acetate, pH 4.8). (B) Anion exchange chromatography on a 
Mono-Q (HR S/5, Pharmacia) column. A linear gradient of sodium 
chloride (O-O.65 M in 20 min) in 20 mM triethanolamine acetate pH 
7.2 was used for elution. The collected COMT active fraction is 
indicated with a solid line. (C, D) Reversed phase chromatography of 
the COMT active anion exchange chromatography fraction from two 
individual purifications. Chromatography was performed on a TSK 
TMS 250 (0.46 x 3 cm) column using a linear gradient of acetonitrile 
(O-100% in 60 min) in 0.1% TFA. Fractions (COMT) and (‘X’) were 
collected and used for peptide mapping or to raise antibodies. 
varied between 1330 U/mg protein (no inactive ‘X’ 
form of COMT present, see below) and about 
660 U/mg protein (about 50% of the ‘X’ form of 
COMT present). Thus, the highest specific activity ob- 
tained corresponded to a 1330-fold purification from 
the centrifuged liver extract with a total yield of 11% 
(156 U) of enzyme activity. The amount of COMT 
polypeptide in the collected Mono Q fraction (Fig. 3B), 
however, always represented at least 90% of the total 
protein. 
It has been reported that the highly purified COMT 
enzyme is fairly to extremely labile and loses its activity 
rapidly under various conditions [14,17,18]. It has also 
been claimed that the instability of the enzyme is due to 
the oxidation of the free cysteine -SH groups [17]. We 
found, however, that the highly pure enzyme, prepared 
by anion exchange chromatography, was remarkably 
stable and lost only a few percent of its activity during 
storage for 48 h at room temperature. 
For final purification the main COMT fraction from 
the Mono-Q column was subjected to RP- 
chromatography. In all chromatograms, peak ‘COMT’ 
was present and its intensity was related to the amount 
of enzyme activity applied to the RP-column. In SDS- 
PAGE it gave a single band corresponding to a 
molecular mass of 25 kDa (Fig. 2A). In some 
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A B C chromatograms, also an additional double peak was 
present (Fig. 1D) which contained proteins named ‘X’ 
and ‘Y’ having molecular masses of 25 and 37 kDa, 
respectively (Fig. 2B). The quantity of fraction ‘X’ 
(25 kDa) varied from about zero (Fig. 1C) to equal to 
that of peak ‘COMT’ (Fig. 1D). To further identify the 
RP-chromatography fractions, we subjected both 
‘COMT’ and ‘X’ fractions to direct N-terminal se- 
quence analysis and measured their COMT activity 
after drying and rehydration into the enzyme assay buf- 
fer. COMT activity was seen only in fraction ‘COMT’ 
(Fig. 1C and lD), identifying it as the enzyme. The se- 
quence analyses gave no results, which suggested that 
the N-terminus of both ‘X’ and COMT is blocked. 
Because the identity of ‘X’ still remained unclear, we 
raised antibodies both against ‘X’ (contaminated with 
a small amount of ‘Y’) as well as pure COMT. 
Fig. 2. SDS-PAGE of reversed phase chromatography fractions. (A) 
‘X’ from Fig. 1D with a slight ‘Y’ contamination. (B) Combined 
COMT fractions from Fig. lC, D. (C)A standard mixture containing 
proteins with molecular masses of 94, 68, 43, 30, 20.1 and 14.4 kDa. 
Electrophoresis was performed in a 12.5% polyacrylamide gel and 
the gel stained with Coomassie brilliant blue. 
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Fig. 3. Western blots of proteins from reversed phase 
chromatography separated by 12.5% SDS-PAGE. The blotting 
membrane was treated (A) with anti-COMT-antibodies, (B) with 
anti-‘X’-antibodies. Lanes a and c contain the COMT fraction and 
lanes b and d the ‘X’ fraction. 
In Western blotting the COMT as well as ‘X’ an- 
tibodies detected both the purified COMT enzyme and 
the 25 kDa ‘X’ protein (Fig. 3C and 3D) which in- 
dicates that COMT and ‘X’ are the same proteins. 
Alkylation of both the purified COMT and ‘X’ yielded 
further evidence. The alkylated COMT and ‘X’ then 
eluted identically in RP-chromatography (Fig. 4) and 
the alkylated ‘X’ was well separated from the alkylated 
contaminating ‘Y’. The tryptic maps of alkylated 
COMT and ‘X’ were similar (Fig. 5). No difference in 
the primary structure of the peptides from COMT and 
‘X’ could be observed after sequencing peptides cor- 
responding to about 90% (204 amino acids) of the 
primary structure (data not shown). 
Apparently COMT and ‘X’ have a different confor- 
mation due to dissimilar intramolecular disulfide 
A. 
,COMT 
, I 3 
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Fig. 4. Desalting of alkylated (Cvinylpyridine) proteins on a 0.46 x 
3 cm TSK TMS 250 (C,) column. A linear gradient of acetonitrile 
(20-50% in 30 min) in 0.1% TFA was used for elution. (A) 
Alkylated COMT fractions and (B) alkylated ‘X’ with ‘Y’ 
contamination from reversed phase chromatography. Alkylated 
COMT and ‘X’ were collected and used for tryptic mapping. 
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Fig. 5. Tryptic maps from (A) alkylated COMT and (B) alkylated 
‘X’. Peptides were separated on a 0.46 x 15 cm Vydac 218 TPBS 
column using a linear gradient of acetonitrile (O-60% B in 60 min) 
in 0.1% TFA. Individual peptides were collected and subjected to 
sequence analysis. The four pyridylethyl-cysteine containing peptides 
with different primary structures (l-4) are indicated. 
bonds. Five pyridylethylcysteine containing peptides, 
(1) Cys-Gly-Leu-Leu-Arg, (2) Gly-Ser-Ser-Ser-Phe- 
Glu-Cys-Thr-His-Tyr-Ser-Ser-Tyr-Leu-Glu-Tyr-Met- 
Lys, (3) Tyr-Val-Gln-Gln-Asn-Ala-Lys-Pro-Gly-Asp- 
Pro-Gln-Ser-Val-Leu-Glu-Ala-Ile-Asp-Thr-Tyr-Cys- 
Thr-Gln-Lys, (3*) Cys-Thr-Gln-Lys, (4) Gly-Ala-Tyr- 
Cys-Gly-Tyr-Ser-Ala-Val-Arg were found among the 
sequenced peptides (Fig. 5). Of these, peptide 3* was a 
degradation product of peptide 3. The existence of four 
cysteines in the COMT primary structure has recently 
been confirmed by nucleotide sequencing [20]. To fur- 
ther examine the suggested differences in disulfide 
bonds between COMT and ‘X’, tryptic peptide maps 
were made from the nonalkylated COMT and ‘X’ 
(Fig. 6A and 6B) and all the peptides equenced. All the 
four cysteine-containing peptides could be localized in 
both chromatograms, due to their known primary 
structure. Cysteine peptides 1 and 2 from both COMT 
(Fig. 6A) and ‘X’ (Fig. 6B) coeluted at a retention time 
of 39.5 min. The peaks collected at this retention time 
both gave a double sequence corresponding to an 
equimolar mixture of cysteine peptides 1 and 2. This 
suggests that peptides 1 and 2 are connected to each 
other by disulfide bonds in both COMT and ‘X’. 
10 20 30 40 50 min. 
Fig. 6. Tryptic maps from (A) non-alkylated COMT and (B) non- 
alkylated ‘X’. Separation conditions were as in Fig. 5, but an 
acetonitrile gradient of O-60070 B in 90 min was used for elution. The 
elution positions of the four cysteine containing peptides (l-4) are 
indicated. 
Similarly, sequence analysis showed that cysteine pep- 
tides 3 and 4 from ‘X’ coelute at a retention time of 
50.4 min (Fig. 6B), whereas these peptides from 
COMT eluted at different positions at slightly earlier 
retention times (48.5 min and the shoulder at 48.5 min, 
Fig. 6A). This indicates that cysteine peptides 3 and 4 
are interconnected only in ‘X’ but not in COMT mean- 
ing that two free cysteine -SH groups are present in 
COMT. It has been reported that a free cysteine SH- 
group at the active center is required for the enzymatic 
reaction [17]. Thus COMT and ‘X’ apparently repre- 
sent the active and inactive form of the enzyme. 
Whether these two forms are physiologically impor- 
tant, or are caused by different external conditions dur- 
ing the purification, remains at present unclear. 
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